The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 462.50
High: 462.50
Low: 462.50
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Study shows Tristel Wipes System benefits

11 Oct 2016 07:00

RNS Number : 1596M
Tristel PLC
11 October 2016
 

 

 

Tristel plc

("Tristel" or "the Company")

 

Comparison of high-level disinfectants for flexible nasendoscopes published in

The Journal of Laryngology & Otology

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that in a randomised, single-blind comparison of disinfectants used in Ear, Nose and Threat clinics, its Wipes System proved to be the equal in terms of microbiological efficacy to disinfectants produced by Du Pont and Johnson & Johnson. In the study Du Pont's PeraSafe peracetic acid disinfectant was used in a tray, and Johnson & Johnson's Cidex OPA ortho phthalaldehyde disinfectant was used in an automated washer-disinfector manufactured by Medvators Inc. The Tristel Wipes System is a stand-alone process requiring no equipment, support building services, or maintenance. The study concluded that the Wipes System has no capital outlay cost, the lowest running cost, the greatest convenience, and the fastest turnaround time for medical instruments of the three products evaluated.

 

The study, which was conducted by the Bay of Plenty District Health Board, Tauranga, New Zealand in 2011 has been published in the The Journal of Laryngology & Otology [Hitchcock, B., Moynan, S., Frampton, C., Reuther, R., Gilling, P. and Rowe, F. (2016) 'A randomised, single-blind comparison of high-level disinfectants for flexible nasendoscopes', The Journal of Laryngology Otology, pp. 1-7. doi: 10.1017/S0022215116008860]. Preliminary results of the study were presented at the 11th Congress for German Hospital Hygiene held in Berlin in March 2012, and reported by an RNS Reach on 29 March 2012.

 

The Tristel Wipes System is a unique, patented decontamination method for non-lumened scopes and probes. It has been a very significant sales success for the Company globally. Worldwide sales in the financial year ending June 2012 were £3.3m and are expected to be £8.7m in the year ending June 2016.

 

Paul Swinney, CEO, comments: "We are pleased to see at long last the publication in a peer-reviewed journal of this significant study comparing our Wipes System with competitor products manufactured by two of the world's major infection prevention companies. The results affirm the key advantages of our Wipes over alternative chemistries and disinfection methods. This is the twenty-fifth peer-reviewed and published scientific paper featuring Tristel products - a body of evidence of our products' attributes that forms one of our Company's key strengths."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

 

Liz Dixon, Finance Director

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

finnCap

Tel: 020 7600 1658

Geoff Nash/ Giles Rolls (Corporate Finance)

 

Stephen Norcross (Corporate Broking)

 

   

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAAKKDQPBDDKKD
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.